Quantcast
Last updated on April 17, 2014 at 16:26 EDT

Latest Bare-metal stent Stories

2009-12-08 13:34:00

NEW YORK, Dec. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries) http://www.reportlinker.com/p0166835/European-Markets-for-Drug-Eluting-and-Bare-Metal-Stents-2009-15-Countries.html The European market, as defined in this report, encompasses Germany, France, the United Kingdom (U.K.), Italy, Spain, Benelux (Belgium, Netherlands, and Luxemburg),...

2009-12-08 13:21:00

NEW YORK, Dec. 8 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Markets for Interventional Cardiology 2009 (15 Countries) http://www.reportlinker.com/p0166830/European-Markets-for-Interventional-Cardiology-2009-15-Countries.html In 2008, the European market for interventional cardiology was valued at over Euro1.5 billion. The interventional cardiology market includes drug-eluting stents, bare-metal stents, PTCA...

2009-11-18 10:50:00

NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Drug-Eluting Stents - Global Market Opportunities http://www.reportlinker.com/p0164240/Drug-Eluting-Stents---Global-Market-Opportunities.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Increasing acceptance of stents as viable treatment option, expanding patient population seeking drug-eluting stents, and higher reimbursement coverage...

2009-09-25 13:39:00

NATICK, Mass. and SAN FRANCISCO, Sept. 25 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced two-year follow-up data from the HORIZONS-AMI trial. The trial, sponsored by the Cardiovascular Research Foundation (CRF) with grant support from Boston Scientific and The Medicines Company (Nasdaq: MDCO), is designed to determine the safety and efficacy of the TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary Stent System compared to bare-metal stenting in patients...

2009-09-16 16:24:00

NATICK, Mass., Sept. 16 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and press announcements at the Cardiovascular Research Foundation's (CRF) 21st annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, which runs from September 21 to 25 in San Francisco. "We look forward to the presentation of additional clinical data reinforcing the safety, efficacy and deliverability of our two distinct...

2009-08-27 15:01:00

NATICK, Mass., Aug. 27 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced the schedule of the Company's major events and news announcements for the European Society of Cardiology (ESC) Congress, which runs from August 29 to September 2 in Barcelona. Highlights include final results from the MADIT-CRT trial and two-year results from the SYNTAX trial. "Boston Scientific is proud to be the exclusive sponsor of the landmark MADIT-CRT trial, and we look...

2009-06-23 15:07:00

Advanced Platinum Surface Maximizes Biocompatibility and Biostabilityin a Bare-Metal Stent BURLINGTON, Mass., June 23 /PRNewswire/ -- CorNova Inc. today announced that it has received CE mark approval for its Valecor Platinum Coronary Stent System. (Logo: http://www.newscom.com/cgi-bin/prnh/20070206/CLTU213LOGO ) The Valecor Platinum is a next-generation cobalt-chromium bare-metal stent. Utilizing a novel ion-based implantation technology called Nanofusion(TM), the Valecor Platinum...

2009-06-23 07:00:00

Broad Size Matrix of XIENCE PRIME to be Launched in Europe in the Third Quarter ABBOTT PARK, Ill., June 23 /PRNewswire-FirstCall/ -- Abbott announced today that it has received CE Mark (Conformite Europeenne) for its next-generation XIENCE PRIME(TM) Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease. The company plans to launch XIENCE PRIME in a broad size matrix with lengths up to 38 mm in Europe in the third quarter. "XIENCE PRIME leverages and will...

2009-05-27 10:54:00

VANCOUVER, May 27 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. It was approved for use in...

2009-05-27 07:30:00

NATICK, Mass., May 27 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Atom(TM) Paclitaxel-Eluting Coronary Stent System, a highly deliverable, next-generation drug-eluting stent (DES) specifically designed for treating small coronary vessels. It was approved for use in vessels as small as 2.25 mm in diameter and joins the TAXUS(R) Express(R) Atom(TM)...